ALX Oncology
ALXO
94 hedge funds and large institutions have $218M invested in ALX Oncology in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 11 closing their positions.
18,100% more call options, than puts
Call options by funds: $182K | Put options by funds: $1K
236% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 11
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
36% more funds holding
Funds holding: 69 → 94 (+25)
15% more capital invested
Capital invested by funds: $189M → $218M (+$28.9M)
6.54% more ownership
Funds ownership: 71.63% → 78.17% (+6.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.4M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$10.3M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.11M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.37M |
| 5 |
JP Morgan Chase
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$13.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.01M |
| 3 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$2.93M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.16M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.23M |
ALXO Hedge Fund Activity: Q2 2026 in Review
94 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2026, worth a combined $218M — up 15% from $189M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ALXO positions and 11 closed out — a net gain of 26 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $12.4M. The largest seller was TCG Crossover Management, cutting an estimated $13.2M.
- 94 institutional investors held ALX Oncology (ALXO) as of Q2 2026, up from 69 in Q1 2026.
- Funds reported $218M of ALX Oncology stock for Q2 2026, up 15% quarter-over-quarter.
- 37 funds opened new ALX Oncology positions in Q2 2026 and 11 closed out, a net change of +26 holders.
- The largest ALX Oncology buyer in Q2 2026 was BlackRock, an estimated $12.4M added.
- The largest ALX Oncology seller in Q2 2026 was TCG Crossover Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2026.